Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Assets (2018 - 2025)

Historic Current Assets for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $5.6 million.

  • BioNexus Gene Lab's Current Assets fell 2006.76% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 2006.76%. This contributed to the annual value of $7.4 million for FY2024, which is 765.96% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Current Assets stood at $5.6 million, which was down 2006.76% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Current Assets ranged from a high of $8.3 million in Q3 2023 and a low of $5.2 million during Q2 2023
  • For the 5-year period, BioNexus Gene Lab's Current Assets averaged around $6.8 million, with its median value being $7.0 million (2024).
  • As far as peak fluctuations go, BioNexus Gene Lab's Current Assets surged by 92778.31% in 2021, and later plummeted by 2692.79% in 2022.
  • BioNexus Gene Lab's Current Assets (Quarter) stood at $7.1 million in 2021, then decreased by 15.78% to $6.0 million in 2022, then soared by 33.63% to $8.0 million in 2023, then fell by 7.66% to $7.4 million in 2024, then dropped by 24.27% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $6.4 million for Q2 2025, and $6.5 million during Q1 2025.